Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
Zepbound , the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Lilly's Taltz and Zepbound used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
Lilly's Retevmo delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Lilly's Retevmo delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Transition Metals Resampling Highlights Broad Gold Intervals at Gowganda Project, Indicating Potential for a Larger Resource Opportunity
Nevada Sunrise Identifies Gold-in-Soil Anomalies over New Target Areas at the Griffon Gold Mine Project, Nevada
